Geriatric oncology and cognition: optimizing outcome for older people

Cognition defines treatment success

In older adults with cancer, treatment success includes survival, disease control, cognition, function, independence, and quality of life. Cognition influences decision-making, medication management, symptom recognition, rehabilitation, hospitalization risk, and maintenance of meaningful daily activities.

CGA guides individualized oncologic care

Comprehensive geriatric assessment before treatment identifies vulnerabilities beyond routine screening and informs treatment personalization. Integrated CGA care improves quality of life, supports treatment completion, reduces severe chemotherapy toxicity, and increases supportive and non-oncological interventions when appropriate.

Cognition requires longitudinal monitoring

Cognitive screening alone is insufficient. Cognition is assessed as a structured, actionable, longitudinal clinical pathway before, during, and after treatment, with reassessment after clinical changes, delirium prevention, caregiver involvement, medication review, and evaluation of functional impact and reversible causes.

In the seminar “Geriatric oncology and cognition: optimizing outcome for older people,” organized by Klinik Barmelweid, MD, MBA Vincenza Frisardi presents cognition as a central determinant of treatment success in older adults with cancer. She argues that conventional oncologic endpoints such as tumor response, survival, and toxicity remain essential, but are insufficient if treatment is accompanied by cognitive decline, loss of independence, and reduced quality of life. Dr. Frisardi emphasizes that cognition influences decision-making capacity, medication management, symptom recognition, rehabilitation, social functioning, and hospitalization risk, and should therefore be integrated into geriatric oncology as a structured, longitudinal clinical domain rather than reduced to a binary screening item. She advocates comprehensive geriatric assessment before, during, and after treatment to identify vulnerabilities, personalize treatment intensity, involve caregivers, and guide interventions such as medication review, mobility support, sleep optimization, and delirium prevention. The lecture highlights that cognitive impairment is an independent prognostic factor but should not lead to therapeutic exclusion; instead, it should prompt supported autonomy, closer monitoring, and adapted communication. Dr. Frisardi also underlines current evidence gaps, particularly regarding long-term cognitive and functional outcomes, and calls for longitudinal and qualitative research to better distinguish pre-existing vulnerability from treatment-related decline. Overall, the seminar reframes therapeutic success in geriatric oncology as the alignment of disease control with preservation of cognition, function, patient goals, and meaningful survivorship.